000			05764cam a2200637Mi 4500
001			ocn794328376
003			OCoLC
005			20221128211740.0
006			m d
007			cr |n|---|||||
008			120528s2012 si ob 001 0 eng d
040			_aEBLCP _beng _epn _cEBLCP _dOCLCQ _dLGG _dYDXCP _dN$T _dIDEBK _dOCLCQ _dCDX _dDEBSZ _dOCLCQ _dE7B _dSTF _dOCLCF _dDEBBG _dUKDOC _dOCLCQ
019			_a793804672 _a794902679 _a797852507 _a817084766
020			_a9789814317467 _q(electronic bk.)
020			_a9814317462 _q(electronic bk.)
020			_a1280669225
020			_a9781280669224
020			_z9789814317450
020			_z9814317454
035			_a(OCoLC)794328376 _z(OCoLC)793804672 _z(OCoLC)794902679 _z(OCoLC)797852507 _z(OCoLC)817084766
043			_an-cn---
072		7	_aMED _x071000 _2bisacsh
072		7	_aTEC _x010010 _2bisacsh
072		7	_aMMG _2bicssc
049			_aMAIN
100	1		_aKilleen, Matthew J.
245	1	0	_aCardiac Drug Safety _h[electronic resource] : _ba Bench to Bedside Approach.
260			_aSingapore : _bWorld Scientific, _c2012.
300			_a1 online resource (189 pages)
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
505	0		_aForeword; "Et causae quoque aestimatio saepe morbum solvit"* [Celsus: Prooemium 69, De Medicina]; Preface; Chapter 1 Challenges Facing the Pharmaceutical Industry in the 21st Century; Introduction; The Impact of Cardiac Toxicity on the Pharmaceutical Industry; References; Chapter 2 The Cellular Basis of Cardiac Electrophysiology; Introduction; The Initiation of the Heart Beat; The Ventricular Cardiac Action Potential; The Relationship Between the Cardiac Action Potential and the Electrocardiogram; Ion Channels Underlying the Cardiac Action Potential; Sodium channels.
505	8		_aCalcium channelsPotassium channels; Cardiac potassium channels; The transient outward potassium channel; Delayed rectifier potassium channels; The ultra rapid delayed rectifier potassium channel; The HERG potassium channel; The slowly activating delayed rectifier potassium channel; Inwardly rectifying potassium channels; Species-dependent variability of potassium channels; Potassium channel subunits; Summary; References; Chapter 3 Clinical Arrhythmia Syndromes; Introduction; The Long QT Syndrome; Congenital Long QT Syndrome; Drug-Induced QT Prolongation; Summary; References.
505	8		_aChapter 4 The Mechanisms Underlying Cardiac ArrhythmiasIntroduction; Mechanisms Underlying Cardiac Arrhythmias; Abnormal Automaticity; Early and Delayed Afterdepolarizations; Re-entry; Transmural Dispersion of Repolarization; How does Action Potential and QT Prolongation Generate Arrhythmias?; Does the M-Cell Play a Role in Arrhythmia Induction in Humans?; Using Mouse Models to Study Arrhythmia Mechanisms; Experimental Studies Exploring the Relationship Between Changes in Transmural Repolarization Gradients and Arrhythmias in Mouse Hearts.
505	8		_aArrhythmia Mechanisms and Novel Antiarrhythmic Approaches Identified Using the Hypokalemic Mouse ModelSummary; References; Chapter 5 The Mechanisms Underlying Drug-Induced Arrhythmias; Introduction; The Classical Model of Drug-Induced QT Prolongation and Proarrhythmia: HERG Blockade; Additional Mechanisms Contributing to Drug-Induced Arrhythmias; Drug-Induction Activation of Depolarizing Ion Channels; Drug-Induced Changes in Ion Channel Expression; Drug-Induced Sodium Channel Dysfunction; Summary; References; Chapter 6 Assessing Cardiac Safety in Drug Development; Introduction.
505	8		_aPreclinical Evaluation of Cardiac Drug SafetyThe ICH S7B Guidelines; Single Cell Safety Studies; The Purkinje Fiber Model; The Ventricular Wedge Model; Isolated Heart Models; In Vivo Models; The Impact of Species-Related Differences in Cardiac Electrophysiology on Preclinical Drug Safety Assessment; Methods to Provoke Arrhythmias in Preclinical Studies; Programmed electrical stimulation; Reductions in the extracellular K+ concentration; Clinical Evaluation of Cardiac Safety; The Thorough QT study; Thorough QT study design; Additional Biomarkers to Detect Drug-Induced Proarrhythmia.
500			_aVariability of repolarization.
520			_aEnsuring the safety of new medical products remains a major challenge for the pharmaceutical industry. Cardiac safety, particularly drug-induced heart rhythm abnormalities, remains an important cause of pipeline attrition and has resulted in countless major product recalls or label changes. The risk of encountering this major adverse event continues to shape the drug development and regulatory landscape. Extensive research over the past decade has shed light on the root causes of arrhythmias that are triggered by medications and has helped drive, and optimize, drug safety testing. However, curr.
588	0		_aPrint version record.
504			_aIncludes bibliographical references and index.
650		0	_aArrhythmia _xTreatment.
650		0	_aDrugs _xSafety regulations _zCanada.
650		2	_aHeart _xdrug effects.
650		2	_aDrug Toxicity _xprevention & control.
856	4	0	_uhttps://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=457178 _yKingston Hospital NHS Foundation Trust OpenAthens account holders click here for access
938			_a123Library _b123L _n114800
938			_aCoutts Information Services _bCOUT _n23981151
938			_aEBL - Ebook Library _bEBLB _nEBL919080
938			_aebrary _bEBRY _nebr10563572
938			_aEBSCOhost _bEBSC _n457178
938			_aIngram Digital eBook Collection _bIDEB _n364615
938			_aYBP Library Services _bYANK _n7280427
942			_n0
994			_a92 _bN$T
999			_c90410 _d90410